多西紫杉醇联合顺铂治疗晚期非小细胞肺癌临床观察  

Clinical Observation of Taxotere Plus Cisplatin Combination in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：王延红[1] 温建成[2] 卢雨霖[1] 李若英[1] 韦爱纯[1] 

机构地区：[1]广东省潮州市中心医院肿瘤内科,521000 [2]广东省潮州市中心医院病理科,521000

出　　处：《实用心脑肺血管病杂志》2009年第6期476-477,共2页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的观察多西紫杉醇联合顺铂治疗晚期非小细胞肺癌（NSCLC）的疗效及不良反应。方法选择我院收治72例晚期NSCLC患者，均给予多西紫杉醇75mg／m^2，第一天持续静脉滴注1h，并在治疗前一天开始口服地塞米松8mg，2次／d，持续3d，顺铂25mg／m^2，1—3d静脉滴注，21d为1个周期，每例患者治疗2个周期以上评价疗效。结果两组无CR，PR31例，SD24例，PD17例，总有效率（CR＋PR）为43．05％。初治组有效率为45．45％。复治组有效率为41．03％，两组间比较差异无统计学意义（P〉0．05）。最常见的不良反应为骨髓抑制，Ⅲ～Ⅳ度白细胞下降占29．16％，Ⅲ度血小板下降占5．56％，无Ⅲ-Ⅳ度血红蛋白下降，非血液学不良反应轻微。结论多西紫杉醇联合顺铂一线治疗或二线治疗晚期非小细胞肺癌均有较好疗效，不良反应可以耐受。Objective To observe the response rate and toxicity of taxotere plus cisplatin combination in the treatment of advanced non - small cell lung cancer （NSCLC）. Methods A total of 72 cases was included in the study. Taxotere was given 75mg/m^2 introvenously on dl, and cisplatin 25mg/m^2 introvenously on d1-3 of each cycle, 21 days for each cycle. Each patient should complete two cycles. Results An objective response rate was obtained in 43.05% of 72 patients. The response rate was 45.45% in the initial patients, and 41.03% in the retreated patients. No significant difference existed between the two groups （ P 〉0. 0S）. The main toxicity was hematological： Grade Ⅲ～Ⅳ leukopoenia was 29. 16%, GradeⅢthrombocytopenia was 5.56%. The non - hematological toxicity was mild. Conclusion Taxotere plus cisplatin is effective and well - tolerated in the first - line or second - line treatment of advanced NSCLC.

关 键 词：多西紫杉醇 顺铂 肺肿瘤 化疗 

分 类 号：R734.2[医药卫生—肿瘤]